Full-Time

National Account Executive

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Biopharma developing kinase inhibitors for cancer

Compensation Overview

$215k - $280k/yr

+ Incentive compensation

Salt Lake City, UT, USA + 8 more

More locations: Las Vegas, NV, USA | Seattle, WA, USA | San Francisco, CA, USA | Los Angeles, CA, USA | Phoenix, AZ, USA | Denver, CO, USA | Portland, OR, USA | San Diego, CA, USA

In Person

Category
Sales & Account Management (1)
Requirements
  • Bachelor’s degree
  • 10-12+ years relevant experience in payer account management
  • Valid Driver’s License
  • Position requires up to 60% travel
Responsibilities
  • Deliver clinical and economic value propositions for Blueprint products to key individuals within assigned accounts to ensure optimal access and reimbursement for Blueprint products.
  • Analyze and understand payer environment, key account business dynamics and priorities, and align Blueprint priorities to create Account plans that deliver activities that contribute to the defined business objectives
  • Develop and implement strategic account business plans in partnership with other key Blueprint team members including sales, precision medicine, brand teams, etc.
  • Develop and grow business partnerships and relationships with Key C-Suite and administrative roles within an account (CEO, CFE, CMO, Director of Pharmacy, Director of Quality, Director of Actuarial Planning, Director of Case Management, Director Industry Relations, etc.) within assigned national accounts
  • Develop a strong understanding and in-depth knowledge of Blueprint disease state areas
  • Strategically deploys resources (individual skills and company resources) before, during and after the formulary development process to maximum impact within the account
  • Review and analyze product performance at the national and regional level and communicate account performance broadly with commercial business colleagues, brand teams and leadership.
  • Monitor competitive landscapes, formulary changes, and policy developments
  • Seek out opportunities for partnership to achieve both Blueprint and customer goals
  • Understand and engage in key local, national health care issues/strategies, customer issues/trends and best practices to establish credibility beyond product and therapeutic areas
  • Negotiate and manage product rebate cycles, contracts with direct customers when appropriate
  • Maintain open communication throughout the organization especially in regard to cross-functional customer efforts
  • Exercise sound judgment and oversight to ensure integrity and compliance with company policies in all activities and communications
  • Adhere to relevant regulatory and compliance guidelines and Company policies
  • Attend/staff/participate in congresses, industry meetings and/or conferences as requested by management
  • Perform other responsibilities as assigned.
Desired Qualifications
  • MBA or Phar.D. preferred
  • 6+ years National Account experience highly desired
  • In-depth knowledge of payer landscape
  • Previous experience managing large payer accounts - (OptumRx, United Health care, Kaiser preferred)
  • Established relationships with existing accounts
  • Demonstrated excellence in understanding of accounts including: Marketing strategy, Medical and Pharmacy reimbursement systems, Organization for health care delivery, Processes for disease management and outcomes research
  • Proven experience implementing pull-through programs
  • Previous experience within the oncology and/or orphan/rare disease space
  • Outstanding oral and written communication skills
  • Inherent understanding of Commercial, Medicare Part D, and Medicaid reimbursement as well as the pharmaceutical regulatory environment
  • Ability to think strategically, compliantly and bring a high level of creativity to the organization
  • Proven record of collaborative, team-oriented approach
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi $9.1B acquisition on June 2, 2025, boosts immunology portfolio and resources.
  • AI and machine learning enhance drug discovery productivity since recent integration.
  • Targeted protein degradation expansion via 2022 VantAI collaboration diversifies pipeline.

What critics are saying

  • Sanofi integration disrupts sales force, eroding Ayvakit market share in 12-18 months.
  • FDA black box warnings for Ayvakit hemorrhage drop prescriptions 20-30% in 6-12 months.
  • Generic avapritinib from Dr. Reddy's captures 40% GIST market by 2028.

What makes Blueprint Medicines unique

  • Ayvakit is the only FDA-approved treatment targeting PDGFRA D842V mutations in GIST.
  • PIONEER four-year data confirm AYVAKIT's sustained efficacy in indolent systemic mastocytosis.
  • BLU-808 shows wide therapeutic window as first-in-class oral wild-type KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Blueprint Medicines who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

5%

2 year growth

3%
Fusacq
Jun 2nd, 2025
Sanofi Acquires Blueprint Medicines Biotech

Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.

Google
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.

Investors Hangout
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.

The Gazette
Jun 2nd, 2025
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...